All
A Deeper Look Into a 40-Year-Old Bladder Cancer Treatment: Bacillus Calmette-Guerin
August 23rd 2018CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.
FDA Grants Empliciti Combination a Priority Review for Myeloma Treatment
August 23rd 2018The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor (PI).
Sometimes, Taking Care of Yourself Is Enough After Cancer
August 21st 2018Wistfully, I recall the days I could work all day, come home and do things around the house and then go out for dinner! Those days are long gone. I am off the chemo this week, but next week I will feel even more fatigue when I go back on.
Personalizing Pain Management and Palliative Care in Ovarian Cancer
August 21st 2018A common goal for palliative care is pain management, where opioids like morphine are often on the frontline. Then, practitioners may build on medications from there, adding agents such as gabapentin and tricyclic antidepressants. But if those don’t work, Christopher J. Pietras, M.D. said that ketamine may be an option.
PARP Inhibitor May Prolong Survival in Metastatic, BRCA-positive Breast Cancer
August 21st 2018Talazoparib reduced the risk for disease progression or death by 46 percent and improved quality of life compared with chemotherapy in a subgroup of women with breast cancer, according to the phase 3 EMBRACA trial results.
FDA Grants Full Approval for Keytruda Combination in Lung Cancer
August 20th 2018The Food and Drug Administration (FDA) has granted a full approval to frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), based on findings from the phase 3 KEYNOTE-189 trial.
Immunotherapy in Bladder Cancer: FDA Updates Labels, Approves Diagnostic Tools
August 17th 2018The Food and Drug Administration (FDA) updated the prescribing information for two immunotherapy agents – Keytruda (pembrolizumab) and Tecentriq (atezolizumab) – approved to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-based therapy.
High Frequency of Common Skin Cancer May Warrant More Intensive Cancer Screening
August 15th 2018Individuals diagnosed with a high frequency of basal cell carcinomas, a common type of skin cancer, may be at an increased for developing an unrelated cancer, highlighting the need for additional clinical screening.
Understanding the Cognitive Side Effects of Cancer and Its Therapies
August 15th 2018Although it may be more difficult to weigh the pros and cons of therapy in light of potential chemo brain than when considering other possible side effects, it still should be a part of the equation. This is especially true because numerous strategies may help ease chemo brain once (or if) it arises.